LeMaitre Vascular (LMAT) director exercises 7,500 stock options

Q: What insider transaction is reported for LeMaitre Vascular (LMAT)?

A director of LeMaitre Vascular, Inc. (LMAT) exercised a stock option and acquired 7,500 shares of common stock on 11/21/2025.

Q: At what price were the LMAT stock options exercised in this Form 4?

The 7,500 stock options were exercised at an exercise price of $37.29 per share, as reported in Table II.

Q: What were the key terms of the exercised LMAT stock option?

The exercised stock option had an exercise price of $37.29, covered 7,500 underlying common shares, was fully vested and exercisable, and had an original grant date of 12/02/2020 with an expiration date of 12/02/2025.

Q: What does the Form 4 say about remaining derivative securities for this LMAT option grant?

Following the transaction, the Form 4 reports 0 derivative securities beneficially owned from this specific stock option grant.

Q: What is the relationship of the reporting person to LeMaitre Vascular (LMAT)?

The reporting person is identified as a Director of LeMaitre Vascular, Inc. on the Form 4.

LeMaitre Vascular, Inc. (LMAT) reported an insider equity transaction by a director.

Filing Impact

(Moderate)

Filing Sentiment

(Positive)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

LeMaitre Vascular, Inc. (LMAT) reported an insider equity transaction by a director. On 11/21/2025, the reporting person exercised a stock option to buy 7,500 shares of common stock at an exercise price of $37.29 per share, as shown in Table II. These shares, reported in Table I, were acquired and increased the director’s directly owned common stock holdings to 64,801 shares following the transaction. The option, originally granted on 12/02/2020 and fully vested and exercisable, was due to expire on 12/02/2025 and shows 0 derivative securities remaining from this grant after the exercise.

Insider Trade Summary

7,500 shares exercised/converted

Exercise 2 txns

Insider O'Connor John James

Role Director

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	7,500	$0.00	$0.00
Exercise	Common Stock	7,500	$37.29	$280K

Holdings After Transaction: Stock Option (Right to Buy) — 0 contracts (Direct); Common Stock — 64,801 shares (Direct)

Footnotes (2)

F1. Represents shares acquired upon exercise of options by the Reporting Person, as reported in Table II.
F2. This option is fully vested and exercisable.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction is reported for LeMaitre Vascular (LMAT)?

A director of LeMaitre Vascular, Inc. (LMAT) exercised a stock option and acquired 7,500 shares of common stock on 11/21/2025.

At what price were the LMAT stock options exercised in this Form 4?

The 7,500 stock options were exercised at an exercise price of $37.29 per share, as reported in Table II.

How many LMAT shares does the insider own after this transaction?

After acquiring shares through the option exercise, the director beneficially owns 64,801 shares of LMAT common stock directly.

What were the key terms of the exercised LMAT stock option?

The exercised stock option had an exercise price of $37.29, covered 7,500 underlying common shares, was fully vested and exercisable, and had an original grant date of 12/02/2020 with an expiration date of 12/02/2025.

What does the Form 4 say about remaining derivative securities for this LMAT option grant?

Following the transaction, the Form 4 reports 0 derivative securities beneficially owned from this specific stock option grant.

What is the relationship of the reporting person to LeMaitre Vascular (LMAT)?

The reporting person is identified as a Director of LeMaitre Vascular, Inc. on the Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 11/21/2025 - 05:55 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

O'Connor John James

(Last)

(First)

(Middle)

C/O LEMAITRE VASCULAR, INC.

63 SECOND AVENUE

(Street)

BURLINGTON

01803

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
LEMAITRE VASCULAR INC [ LMAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/21/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	11/21/2025		M		7,500⁽¹⁾	A	$37.29	64,801	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$37.29	11/21/2025		M			7,500	12/02/2020⁽²⁾	12/02/2025	Common Stock	7,500	$0	0	D

Explanation of Responses:

1. Represents shares acquired upon exercise of options by the Reporting Person, as reported in Table II.

2. This option is fully vested and exercisable.

	/s/ Laurie A. Churchill, Attorney-in-fact	11/21/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR